Stockholm, 28 January 2026 — Sigrid Therapeutics (Sigrid), a science-driven consumer health company developing innovative solutions for metabolic health, today announced the appointment of Claus Kjaersgaard as its new Chief Executive Officer. Claus will assume the role on 1 February 2026.
Claus brings more than 15 years of experience across marketing, sales, and business development within FMCG, pharmaceuticals, and healthcare. Most recently, he served as CEO of Otivio AS, where he led the company’s global commercial strategy for medical devices. He previously served as CEO of Smartfish AS and has held senior roles at Pronova BioPharma and GlaxoSmithKline.
“I am thrilled to join Sigrid at a pivotal moment for the metabolic health category, said Claus Kjaersgaard. “With its patented SiPore® technology, Sigrid is uniquely positioned to help reshape and revitalise this space in a more sustainable, science-led way.”
Mattias Ankarberg, Chairman of the Board of Sigrid, commented:
“I am very pleased to welcome Claus Kjaersgaard as our new CEO. Claus has a strong track record of building and scaling health-focused businesses, combining strategic clarity with deep customer and market insight. His experience across regulated health products, international commercialisation, and partnership-driven growth makes him exceptionally well suited to lead Sigrid into its next phase. I would also like to thank Sana Alajmovic for building the strong scientific and commercial foundation of Sigrid and wish her the very best in her next role.”
About Sigrid Therapeutics (Sigrid)
Sigrid is a Swedish, science-driven consumer health company developing novel, non-systemic technologies to address major everyday health challenges. Built on the patented SiPore® platform, Sigrid’s portfolio includes products for metabolic health, such as Carb Fence and Glucose Stabiliser, with additional applications enabled through strategic partnerships.
